Daiichi gets ODAC split, with FDA panel backing pexidartinib for rare cancer

Missing data and lingering safety questions dogged a pair of Daiichi Sankyo oncology agents that came before ODAC on Tuesday, but a lack of available treatment options for tenosynovial giant cell tumor and a clear win on the primary endpoint for pexidartinib swayed the FDA panel in favor of approval 12-3. Quizartinib, to treat relapsed, refractory FLT3-ITD-positive AML, did not fare as well, with the Oncologic Drugs Advisory

Read the full 683 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE